As sup­ply chain wor­ries ease up, Big Phar­ma CEOs have a new top con­cern: re­cruit­ing and keep­ing em­ploy­ees

4 years ago
People
Pharma

NIH spot­lights trio of aca­d­e­m­ic teams chas­ing af­ter 'pan-coro­n­avirus' vac­cines

4 years ago
Discovery

Con­tract re­search is hav­ing a mo­ment right now. Will M&A splash­es dri­ve the in­dus­try to even greater heights?

4 years ago
Outsourcing
In Focus

Safe­ty fears force Pfiz­er to change piv­otal DMD gene ther­a­py tri­al pro­to­col

4 years ago
R&D
Cell/Gene Tx

French biotech and Pfiz­er find pos­i­tives in da­ta for Ly­me dis­ease vac­cine can­di­date; Al­tim­mune's obe­si­ty drug shows ...

4 years ago
News Briefing

Zio­pharm lays off half its staff af­ter man­u­fac­tur­ing is­sues force de­lays

4 years ago
People
Pharma

Covid-19 roundup: Pfiz­er/BioN­Tech sub­mit vac­cine da­ta to FDA for younger chil­dren; Doc­tors kept pre­scrib­ing ...

4 years ago
Coronavirus

George Church, his stu­dents, and top VCs go na­tion­wide with a biotech train­ing camp

4 years ago
Startups

Bank­ing on in­te­grase in­hibitors as HIV cor­ner­stone, Vi­iV bags 3rd-gen­er­a­tion com­pound from Sh­iono­gi

4 years ago
Deals

On a jour­ney to dras­ti­cal­ly speed up cell ther­a­py man­u­fac­tur­ing, Ky­topen lands $30M Se­ries A

4 years ago
Financing
Startups

Sanofi calls it quits on mR­NA Covid-19 shots, scrap­ping vac­cine from $3.2B Trans­late Bio buy­out

4 years ago
R&D
Coronavirus

Tur­moil at CBER: Pe­ter Marks grabs con­trol of FDA's Of­fice of Vac­cines ahead of 2 key ca­reer leader de­par­tures

4 years ago
FDA+
Coronavirus

Look­ing to rewrite the rules of drug li­cens­ing, start­up An­ji is on the hunt for 'dy­nam­ic eq­ui­ty' joint ven­tures

4 years ago
Financing
R&D

In­novent bets $250M+ on Union's PDE4 in­hibitor ahead of a PhII read­out

4 years ago
Deals
China

Seiz­ing Aduhelm prece­dent, Bio­gen, Ei­sai get the ball rolling on an­oth­er ac­cel­er­at­ed Alzheimer's ap­proval

4 years ago
FDA+

Mer­ck emerges as lead bid­der in po­ten­tial Ac­celeron buy­out with deal pos­si­ble this week — re­port

4 years ago
Deals
Pharma

Opin­ion: How the con­fus­ing boost­er shot de­ba­cle aligns Biden with Trump's pan­dem­ic re­sponse

4 years ago
Coronavirus
Opinion

Evelo touts PhII win for in­flam­ma­tion pro­gram; In­novent, An­Heart claim in­ter­im PhII suc­cess in NSCLC

4 years ago
News Briefing

Af­ter pump­ing the brakes on their An­gel­man syn­drome study, Ul­tragenyx and GeneTx are back in the race

4 years ago
FDA+

Bio­gen can't es­cape co­pay kick­back law­suits as Hu­mana al­leges 'seed­ing and sweep­ing' scheme

4 years ago
Pharma

Bio­haven turns out a dud in fa­tal neu­rode­gen­er­a­tive dis­ease, cast­ing doubt on drug's chances in ALS

4 years ago
R&D

Mer­ck touts a con­fir­ma­to­ry Keytru­da win for liv­er can­cer as 'dan­gling' ac­cel­er­at­ed ap­proval saga march­es on

4 years ago
R&D
Pharma

No­vo Nordisk set­tles in­sulin pric­ing suit for $100M

4 years ago
Pharma

A new psy­che­delics play­er emerges to treat men­tal health dis­or­ders — mi­nus the hal­lu­cino­genic ef­fects

4 years ago
Financing
First page Previous page 644645646647648649650 Next page Last page
A service from the Financial Times